Exelixis, Inc.
1851 Harbor Bay Parkway
Alameda
California
94502
United States
Tel: 650-837-7000
Website: http://www.exelixis.com/
842 articles about Exelixis, Inc.
-
Exelixis, Inc. Announces August 5 Webcast of Its Second Quarter 2008 Financial Results and Business Update Conference Call
7/22/2008
-
Exelixis, Inc. Initiates Phase 3 Trial of XL184 in Medullary Thyroid Cancer
7/21/2008
-
Exelixis, Inc. Appoints Frances K. Heller As Executive Vice President of Business Development
7/18/2008
-
Exelixis, Inc. (JOBS) and GlaxoSmithKline (JOBS) Agree to Successfully Conclude Six-Year Discovery and Development Collaboration
6/27/2008
-
Exelixis, Inc. Reaches Agreement with FDA on Special Protocol Assessment for XL184 Phase 3 Trial Pivotal Trial in Medullary Thyroid Cancer Planned to Initiate This Summer
6/16/2008
-
Exelixis, Inc. Reaches Agreement with FDA on Special Protocol Assessment for XL184 Phase 3 Trial
6/16/2008
-
Exelixis, Inc. Announces June 25 Webcast of Presentation at the Piper Jaffray Europe Conference
6/16/2008
-
Exelixis, Inc. Presents Clinical Data Supporting the Safety and Initial Clinical Activity of XL228 in Chronic and Acute Leukemia Compound Inhibits Mutant Forms of BCR-ABL That Cause Resistance to Current CML and ALL Therapies
6/13/2008
-
Exelixis, Inc. Announces June 19 Webcast of Presentation at the William Blair 28th Annual Growth Stock Conference
6/13/2008
-
Exelixis, Inc. Receives $150 Million Funding Commitment From Deerfield Management
6/5/2008
-
Exelixis, Inc. Announces June 10 Webcast of Presentation at the Goldman, Sachs & Co. 29th Annual Global Healthcare Conference
6/4/2008
-
Exelixis, Inc. Reports Positive Clinical Pharmacodynamics Data for PI3K/mTOR Inhibitor XL765 at American Society of Clinical Oncology
6/2/2008
-
Exelixis, Inc. Reports Phase 1 and Phase 2 Data For XL647 at American Society of Clinical Oncology Data Show Activity in First- and Late-Line Treatment of NSCLC
6/2/2008
-
Exelixis, Inc. Reports Encouraging Phase 1 Data for XL184 at American Society of Clinical Oncology; Greater Than 50% Response Rate and 100% Disease Control Rate Observed in Patients with Medullary Thyroid Cancer
6/2/2008
-
Exelixis, Inc. Will Webcast Its June 2 Investor and Analyst Briefing at American Society of Clinical Oncology
5/28/2008
-
Exelixis, Inc. Announces June 2 Webcast of Its ASCO Investor and Analyst Briefing; Seven Abstracts Accepted for Presentation at ASCO
5/22/2008
-
Exelixis, Inc. Announces First Quarter 2008 Financial Results
5/7/2008
-
Exelixis, Inc. Announces May 6 Webcast of Its First Quarter 2008 Financial Results and Business Update Conference Call
4/28/2008
-
Exelixis, Inc. Release: Seven Abstracts Featuring Exelixis Compounds Accepted for Presentation at 2008 American Society of Clinical Oncology Annual Meeting
3/31/2008
-
Exelixis, Inc. Announces March 19 Webcast of Presentation at the Lehman Brothers Annual Global Healthcare Conference
3/17/2008